<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">29220302</PMID>
      <DateCompleted>
        <Year>2019</Year>
        <Month>07</Month>
        <Day>22</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1527-7755</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>36</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2018</Year>
              <Month>Jan</Month>
              <Day>10</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</Title>
          <ISOAbbreviation>J Clin Oncol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Biology and Management of Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma, and Malignant Peripheral Nerve Sheath Tumors: State of the Art and Perspectives.</ArticleTitle>
        <Pagination>
          <StartPage>160</StartPage>
          <EndPage>167</EndPage>
          <MedlinePgn>160-167</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1200/JCO.2017.75.3467</ELocationID>
        <Abstract>
          <AbstractText>Undifferentiated pleomorphic sarcomas, myxofibrosarcomas, and malignant peripheral nerve sheath tumors are characterized by complex genomic characteristics and aggressive clinical behavior. Recent advances in the understanding of the pathogenesis of these tumors may allow for the development of more-effective innovative therapeutic strategies, including immunotherapies. This review describes the current knowledge of the epidemiology, clinical presentation, treatment, and pathogenesis of these tumors and highlights ongoing and future research.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Widemann</LastName>
            <ForeName>Brigitte C</ForeName>
            <Initials>BC</Initials>
            <AffiliationInfo>
              <Affiliation>Brigitte C. Widemann, National Cancer Institute, Bethesda, MD; and Antoine Italiano, Institut Bergonié and University of Bordeaux, Bordeaux, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Italiano</LastName>
            <ForeName>Antoine</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Brigitte C. Widemann, National Cancer Institute, Bethesda, MD; and Antoine Italiano, Institut Bergonié and University of Bordeaux, Bordeaux, France.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2017</Year>
          <Month>12</Month>
          <Day>08</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Clin Oncol</MedlineTA>
        <NlmUniqueID>8309333</NlmUniqueID>
        <ISSNLinking>0732-183X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005354" MajorTopicYN="N">Fibrosarcoma</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023281" MajorTopicYN="N">Genomics</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008080" MajorTopicYN="N">Liposarcoma</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018319" MajorTopicYN="N">Neurofibrosarcoma</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012509" MajorTopicYN="N">Sarcoma</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D057170" MajorTopicYN="N">Translational Research, Biomedical</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
          <QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2017</Year>
          <Month>12</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>7</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2017</Year>
          <Month>12</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">29220302</ArticleId>
        <ArticleId IdType="pmc">PMC5759316</ArticleId>
        <ArticleId IdType="doi">10.1200/JCO.2017.75.3467</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>O’Brien JE, Stout AP: Malignant fibrous xanthomas. Cancer
17:1445-1455, 1964</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14223761</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Le Doussal V, Coindre JM, Leroux A, et al. : Prognostic factors for patients with localized primary malignant fibrous histiocytoma: A multicenter study of 216 patients with multivariate analysis. Cancer
77:1823-1830, 1996</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8646680</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coindre JM, Mariani O, Chibon F, et al. : Most malignant fibrous histiocytomas developed in the retroperitoneum are dedifferentiated liposarcomas: A review of 25 cases initially diagnosed as malignant fibrous histiocytoma. Mod Pathol
16:256-262, 2003</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12640106</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fletcher CD: Pleomorphic malignant fibrous histiocytoma: Fact or fiction? A critical reappraisal based on 159 tumors diagnosed as pleomorphic sarcoma. Am J Surg Pathol
16:213-228, 1992</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1317996</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fletcher CD, Gustafson P, Rydholm A, et al. : Clinicopathologic re-evaluation of 100 malignant fibrous histiocytomas: Prognostic relevance of subclassification. J Clin Oncol
19:3045-3050, 2001</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11408500</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oda Y, Tamiya S, Oshiro Y, et al. : Reassessment and clinicopathological prognostic factors of malignant fibrous histiocytoma of soft parts. Pathol Int
52:595-606, 2002</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12406189</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation> Fletcher CDM, Bridge JA, Hogendoorn P, et al (eds): WHO Classification of Tumours of Soft Tissue and Bone (ed 4). Lyon, France, IARC Press, 2013.</Citation>
        </Reference>
        <Reference>
          <Citation>Henderson MT, Hollmig ST: Malignant fibrous histiocytoma: Changing perceptions and management challenges. J Am Acad Dermatol
67:1335-1341, 2012</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22677489</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gibault L, Pérot G, Chibon F, et al. : New insights in sarcoma oncogenesis: A comprehensive analysis of a large series of 160 soft tissue sarcomas with complex genomics. J Pathol
223:64-71, 2011</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21125665</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carneiro A, Francis P, Bendahl PO, et al. : Indistinguishable genomic profiles and shared prognostic markers in undifferentiated pleomorphic sarcoma and leiomyosarcoma: Different sides of a single coin?
Lab Invest
89:668-675, 2009</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19290004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baird K, Davis S, Antonescu CR, et al. : Gene expression profiling of human sarcomas: Insights into sarcoma biology. Cancer Res
65:9226-9235, 2005</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16230383</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee YF, John M, Edwards S, et al. : Molecular classification of synovial sarcomas, leiomyosarcomas and malignant fibrous histiocytomas by gene expression profiling. Br J Cancer
88:510-515, 2003</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2377178</ArticleId>
            <ArticleId IdType="pubmed">12592363</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abehouse A, Adebamowo C, Adebamowow SN, et al. : Comprehensive and integrated genomic characterization of adult soft tissue sarcomas. Cell
171:950-965.e28, 2017</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5693358</ArticleId>
            <ArticleId IdType="pubmed">29100075</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pérot G, Chibon F, Montero A, et al. : Constant p53 pathway inactivation in a large series of soft tissue sarcomas with complex genetics. Am J Pathol
177:2080-2090, 2010</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2947301</ArticleId>
            <ArticleId IdType="pubmed">20884963</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang CY, Wei Q, Han I, et al. : Hedgehog and Notch signaling regulate self-renewal of undifferentiated pleomorphic sarcomas. Cancer Res
72:1013-1022, 2012</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22232736</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matushansky I, Hernando E, Socci ND, et al. : Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway. J Clin Invest
117:3248-3257, 2007</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2030456</ArticleId>
            <ArticleId IdType="pubmed">17948129</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spranger S, Bao R, Gajewski TF: Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature
523:231-235, 2015</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25970248</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Delespaul L, Lesluyes T, Pérot G, et al. : Recurrent TRIO fusion in nontranslocation-related sarcomas. Clin Cancer Res
23:857-867, 2017</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27528700</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gronchi A, Ferrari S, Quagliuolo V, et al. : Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): An international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol
18:812-822, 2017</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28499583</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reichardt P: Soft tissue sarcomas, a look into the future: Different treatments for different subtypes. Future Oncol
10:s19-s27, 2014.  (suppl 8)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25048045</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Savina M, Le Cesne A, Blay JY, et al. : Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: The METASARC observational study. BMC Med
15:78, 2017</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5385590</ArticleId>
            <ArticleId IdType="pubmed">28391775</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Willems SM, Debiec-Rychter M, Szuhai K, et al. : Local recurrence of myxofibrosarcoma is associated with increase in tumour grade and cytogenetic aberrations, suggesting a multistep tumour progression model. Mod Pathol
19:407-416, 2006</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16415793</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation> Kaya M, Wada T, Nagoya S, et al: MRI and histological evaluation of the infiltrative growth pattern of myxofibrosarcoma. Skelet Radiol 37:1085-1090, 2008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18629459</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation> Waters B, Panicek DM, Lefkowitz RA, et al: Low-grade myxofibrosarcoma: CT and MRI patterns in recurrent disease. AJR Am J Roentgenol 188:W193-W198, 2007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17242227</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Idbaih A, Coindre JM, Derré J, et al. : Myxoid malignant fibrous histiocytoma and pleomorphic liposarcoma share very similar genomic imbalances. Lab Invest
85:176-181, 2005</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15702084</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okada T, Lee AY, Qin LX, et al. : Integrin-α10 dependency identifies RAC and RICTOR as therapeutic targets in high-grade myxofibrosarcoma. Cancer Discov
6:1148-1165, 2016</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5050162</ArticleId>
            <ArticleId IdType="pubmed">27577794</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Evans DG, Baser ME, McGaughran J, et al. : Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet
39:311-314, 2002</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1735122</ArticleId>
            <ArticleId IdType="pubmed">12011145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferner RE, Gutmann DH: International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res
62:1573-1577, 2002</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11894862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Farid M, Demicco EG, Garcia R, et al. : Malignant peripheral nerve sheath tumors. Oncologist
19:193-201, 2014</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3926794</ArticleId>
            <ArticleId IdType="pubmed">24470531</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uusitalo E, Rantanen M, Kallionpää RA, et al. : Distinctive cancer associations in patients with neurofibromatosis type 1. J Clin Oncol
34:1978-1986, 2016</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26926675</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation> Kim A, Stewart DR, Reilly KM, et al: Malignant peripheral nerve sheath tumors state of the science: Leveraging clinical and biological insights into effective therapies. Sarcoma 2017:7429697, 2017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5448069</ArticleId>
            <ArticleId IdType="pubmed">28592921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation> Reilly KM, Kim A, Blakeley J, et al: Neurofibromatosis type 1-associated MPNST state of the science: Outlining a research agenda for the future. J Natl Cancer Inst 109:djx124, 2017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6057517</ArticleId>
            <ArticleId IdType="pubmed">29117388</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation> Meany H, Widemann B, Ratner N: Malignant peripheral nerve sheath tumors: Prognostic and diagnostic markers and therapeutic targets, in Upadhyaya M, Cooper D (eds): Neurofibromatosis Type 1. Berlin, Germany, Springer, 2012, pp 445-467.</Citation>
        </Reference>
        <Reference>
          <Citation>Mautner VF, Asuagbor FA, Dombi E, et al. : Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1. Neuro-oncol
10:593-598, 2008</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2666233</ArticleId>
            <ArticleId IdType="pubmed">18559970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dombi E, Solomon J, Gillespie AJ, et al. : NF1 plexiform neurofibroma growth rate by volumetric MRI: Relationship to age and body weight. Neurology
68:643-647, 2007</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17215493</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim A, Gillespie A, Dombi E, et al. : Characteristics of children enrolled in treatment trials for NF1-related plexiform neurofibromas. Neurology
73:1273-1279, 2009</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2764415</ArticleId>
            <ArticleId IdType="pubmed">19841379</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation> Nguyen R, Kluwe L, Fuensterer C, et al: Plexiform neurofibromas in children with neurofibromatosis type 1: Frequency and associated clinical deficits. J Pediatr 159:652-655.e2, 2011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21621223</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beert E, Brems H, Daniëls B, et al. : Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors. Genes Chromosomes Cancer
50:1021-1032, 2011</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21987445</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meany H, Dombi E, Reynolds J, et al. : 18-Fluorodeoxyglucose-positron emission tomography (FDG-PET) evaluation of nodular lesions in patients with neurofibromatosis type 1 and plexiform neurofibromas (PN) or malignant peripheral nerve sheath tumors (MPNST). Pediatr Blood Cancer
60:59-64, 2013</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6626667</ArticleId>
            <ArticleId IdType="pubmed">22645095</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation> Akshintala S, Bhaumik S, Venkatesan A, et al: Identification of lesions concerning for transformation to malignant peripheral nerve sheath tumors (MPNST) in neurofibromatosis 1 (NF1). Radiological Society of North America, 2014.</Citation>
        </Reference>
        <Reference>
          <Citation>Bernthal NM, Putnam A, Jones KB, et al. : The effect of surgical margins on outcomes for low grade MPNSTs and atypical neurofibroma. J Surg Oncol
110:813-816, 2014</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25111615</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation> Miettinen M, Antonescu C, Fletcher C, et al: Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1-a consensus overview. Hum Pathol 67:1-10, 2017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5628119</ArticleId>
            <ArticleId IdType="pubmed">28551330</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patwardhan PP, Surriga O, Beckman MJ, et al. : Sustained inhibition of receptor tyrosine kinases and macrophage depletion by PLX3397 and rapamycin as a potential new approach for the treatment of MPNSTs. Clin Cancer Res
20:3146-3158, 2014</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4060793</ArticleId>
            <ArticleId IdType="pubmed">24718867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu J, Williams JP, Rizvi TA, et al. : Plexiform and dermal neurofibromas and pigmentation are caused by Nf1 loss in desert hedgehog-expressing cells. Cancer Cell
13:105-116, 2008</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2846699</ArticleId>
            <ArticleId IdType="pubmed">18242511</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jessen WJ, Miller SJ, Jousma E, et al. : MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. J Clin Invest
123:340-347, 2013</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3533264</ArticleId>
            <ArticleId IdType="pubmed">23221341</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dombi E, Baldwin A, Marcus LJ, et al. : Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas. N Engl J Med
375:2550-2560, 2016</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5508592</ArticleId>
            <ArticleId IdType="pubmed">28029918</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Raedt T, Walton Z, Yecies JL, et al. : Exploiting cancer cell vulnerabilities to develop a combination therapy for Ras-driven tumors. Cancer Cell
20:400-413, 2011</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3233475</ArticleId>
            <ArticleId IdType="pubmed">21907929</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Malone CF, Fromm JA, Maertens O, et al. : Defining key signaling nodes and therapeutic biomarkers in NF1-mutant cancers. Cancer Discov
4:1062-1073, 2014</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4446704</ArticleId>
            <ArticleId IdType="pubmed">24913553</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gordon DJ, Resio B, Pellman D: Causes and consequences of aneuploidy in cancer. Nat Rev Genet
13:189-203, 2012</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22269907</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hanahan D, Weinberg RA: Hallmarks of cancer: The next generation. Cell
144:646-674, 2011</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21376230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nielsen TO, West RB: Translating gene expression into clinical care: Sarcomas as a paradigm. J Clin Oncol
28:1796-1805, 2010</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20194847</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chibon F, Lagarde P, Salas S, et al. : Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity. Nat Med
16:781-787, 2010</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20581836</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lagarde P, Przybyl J, Brulard C, et al. : Chromosome instability accounts for reverse metastatic outcomes of pediatric and adult synovial sarcomas. J Clin Oncol
31:608-615, 2013</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23319690</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roschke AV, Lababidi S, Tonon G, et al. : Karyotypic “state” as a potential determinant for anticancer drug discovery. Proc Natl Acad Sci U S A
102:2964-2969, 2005</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC549443</ArticleId>
            <ArticleId IdType="pubmed">15703300</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Munro AF, Twelves C, Thomas JS, et al. : Chromosome instability and benefit from adjuvant anthracyclines in breast cancer. Br J Cancer
107:71-74, 2012</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3389422</ArticleId>
            <ArticleId IdType="pubmed">22644297</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ignatiadis M, Singhal SK, Desmedt C, et al. : Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: A pooled analysis. J Clin Oncol
30:1996-2004, 2012</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22508827</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation> Curiel TJ: Historical perspectives and current trends in cancer immunotherapy, in Curiel TJ (ed): Cancer Immunotherapy, Paradigms, Practice and Promise. New York, NY, Springer, 2013, pp 3-16.</Citation>
        </Reference>
        <Reference>
          <Citation>Coley WB: II. Contribution to the knowledge of sarcoma. Ann Surg
14:199-220, 1891</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1428624</ArticleId>
            <ArticleId IdType="pubmed">17859590</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wiemann B, Starnes CO: Coley’s toxins, tumor necrosis factor and cancer research: A historical perspective. Pharmacol Ther
64:529-564, 1994</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7724661</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gatti RA, Good RA: Occurrence of malignancy in immunodeficiency diseases. A literature review. Cancer
28:89-98, 1971</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">4938894</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Penn I: Sarcomas in organ allograft recipients. Transplantation
60:1485-1491, 1995</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8545879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim C, Kim EK, Jung H, et al. : Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma. BMC Cancer
16:434, 2016</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4938996</ArticleId>
            <ArticleId IdType="pubmed">27393385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation> Kim JR, Moon YJ, Kwon KS, et al: Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas. PLoS One 8:e82870, 2013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3859621</ArticleId>
            <ArticleId IdType="pubmed">24349382</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>D’Angelo SP, Shoushtari AN, Agaram NP, et al. : Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. Hum Pathol
46:357-365, 2015</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5505649</ArticleId>
            <ArticleId IdType="pubmed">25540867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation> Toulmonde M, Adam J, Bessede A, et al: Integrative assessment of expression and prognostic value of PDL1, IDO, and kynurenine in 371 primary soft tissue sarcomas with genomic complexity. J Clin Oncol 34, 2016 (suppl; abstr 11008)</Citation>
        </Reference>
        <Reference>
          <Citation> Bertucci F, Finetti P, Perrot D, et al: PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas. Oncoimmunology 6:e1278100, 2017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5384364</ArticleId>
            <ArticleId IdType="pubmed">28405501</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation> Pollack SM, He Q, Yearley JH, et al: T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas. Cancer 123:3291-3304, 2017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5568958</ArticleId>
            <ArticleId IdType="pubmed">28463396</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation> Tawbi HA, Burgess M, Bolejack V, et al: Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): A multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol 18:1493-1501, 2017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28988646</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation> Toulmonde M, Penel N, Adam J, et al: Use of PD-1 targeting, macrophage infiltration, and IDO pathway activation in sarcomas: A phase 2 clinical trial. JAMA Oncol  10.1001/jamaoncol.2017 [epub ahead of print on June 29, 2017]</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaoncol.2017</ArticleId>
            <ArticleId IdType="pmc">PMC5833654</ArticleId>
            <ArticleId IdType="pubmed">28662235</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
